Repurposing Artesunate to Combat Progression and Metastasis via Targeting Circulating Tumor CellsOA
Objectives:Circulating tumor cells(CTCs)drive metastasis and exhibit resistance to conventional therapies,making them crucial therapeutic targets.Artesunate(AS),a derivative of artemisinin,displays anticancer activity,including inhibition of JunB proto-oncogene(JUNB)and programmed death ligand-1(PD-L1)and upregulation of Vimentin(VIM),markers related to poor prognosis in CTCs.This study aimed to evaluate the effects of AS on adherent and non-adherent cancer cell lines(breast,lung,colon),the patient-derived colon cancer CTC-MCC-41 line,and CTCs from small-cell lung cancer(SCLC)patients.Methods:AS’s effect was evaluated using TetherChip technology.Cell viability was measured using MTT assay,while immunofluorescence staining and the VyCAP platform were applied to characterize and quantify CTCs.Results:AS significantly reduces viability in all tested cell lines in a time-and concentration-dependent manner,with non-adherent cells showing higher resistance.Notably,CTC-MCC-41 cells are the most sensitive to AS treatment.AS demonstrates stronger cytotoxicity than 5-fluorouracil(5-FU)in most cancer models.In SCLC patient samples,AS reduces total CTC counts(p<0.001),eliminates aggressive phenotypes such as(CK+/CXCR4+/JUNB–)and(CK+/VIM+/GLU+),and increases apoptotic(M30+)CTCs(p=0.021).AS additionally impairs structural features like microtentacles,which facilitate CTC reattachment.Conclusions:These findings underscore AS’s ability to target metastasis-competent and anoikis-resistant tumor cells,reducing their viability,invasiveness,and survival mechanisms.AS emerges as a promising candidate for anti-metastatic therapy and warrants further investigation in precision oncology.
Evangelia Pantazaka;Dimitrios Papakonstantinou;Argyro Roumeliotou;Dafni Graikioti;Sotirios Tsakas;Nefeli Zacharopoulou;Stuart SMartin;Athanasios Kotsakis;Constantinos MAthanassopoulos;Catherine Alix-Panabières;Galatea Kallergi
Laboratory of Biochemistry/Metastatic Signaling,Section of Genetics,Cell Biology and Development,Department of Biology,University of Patras,University Campus,Patras,GreeceLaboratory of Biochemistry/Metastatic Signaling,Section of Genetics,Cell Biology and Development,Department of Biology,University of Patras,University Campus,Patras,GreeceLaboratory of Biochemistry/Metastatic Signaling,Section of Genetics,Cell Biology and Development,Department of Biology,University of Patras,University Campus,Patras,GreeceSynthetic Organic Chemistry Laboratory,Department of Chemistry,University of Patras,University Campus,Patras,GreeceLaboratory of Biochemistry/Metastatic Signaling,Section of Genetics,Cell Biology and Development,Department of Biology,University of Patras,University Campus,Patras,GreeceMedical Science Liaison MSL Oncology&Rare Diseases,Medical Department,Ipsen Greece&Cyprus,IPSEN SP LLC,63 Agiou Dimitriou Str.,Alimos–Athens,GreeceDepartment of Pharmacology and Physiology,University of Maryland School of Medicine,Baltimore,MD,USADepartment of Medical Oncology,General University Hospital of Larissa,Larissa,GreeceSynthetic Organic Chemistry Laboratory,Department of Chemistry,University of Patras,University Campus,Patras,GreeceLaboratory of Rare Human Circulating Cells and Liquid Biopsy(LCCRH),University Medical Centre of Montpellier,Montpellier,France CREEC,MIVEGEC,University of Montpellier,CNRS,IRD,Montpellier,France European Liquid Biopsy Society(ELBS),Hamburg,GermanyLaboratory of Biochemistry/Metastatic Signaling,Section of Genetics,Cell Biology and Development,Department of Biology,University of Patras,University Campus,Patras,Greece
医药卫生
Artesunatecirculating tumor cellsanoikismetastasissmall-cell lung cancer(SCLC)TetherChipapoptosis
《Oncology Research》 2026 (6)
P.355-377,23
financed by the Research Council of the University of Patras.The research project was supported by the project SUB3.Applied Research for Precision Medicine through a Non-Profit Organisation(NPO)under Private Law-”Hellenic Precision Medicine Network“(HPMN),which is co-financed by Recovery and Resilience Fund and the Next Generation EU through the General Secretariat for Research and Innovation of the Hellenic Ministry of Development(MIS 5184864).
评论